Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 128.26 |
| Open | 128.01 |
| Bid | 120.00 x 1000 |
| Ask | 134.68 x 900 |
| Day's Range | 127.18 - 128.48 |
| 52 Week Range | 99.14 - 133.10 |
| Volume | |
| Avg. Volume | 8,207,522 |
| Market Cap | 322.987B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 140.12 |
| EPS (TTM) | 0.91 |
| Earnings Date | Jul 30, 2024 |
| Forward Dividend & Yield | 3.08 (2.42%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | 141.42 |
ZacksHere's Why Merck (MRK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insider Monkey15 Best Places to Retire in Florida That You’ve Never Heard Of
This article takes a look at the 15 best places to retire in Florida that you’ve never heard of. If you wish to skip our detailed analysis of financial challenges and hidden gems in Florida, you may go to the 5 Best Places to Retire in Florida That You’ve Never Heard Of. Navigating Financial Challenges […]
Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
© 2024 Yahoo. All rights reserved.